|
ProMetic Drug Demonstrates Positive Results
A third group has been dosed in ProMetic Life Sciences’ Phase II trial of PBI-1402 in patients with chemotherapy-induced anemia. Data from 18 patients showed an overall statistically significant increase of the mean hematocrit values at weeks four, six and eight, according to the Canadian drugmaker. The company has scheduled a separate multicenter, placebo-controlled Phase II study in patients with anemia resulting from chronic kidney disease. |
Register Now
Archives